Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin-associated cholestatic hepatitis

L E Derby1, H Jick, D A Henry

  • 1Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA 02173-5207.

The Medical Journal of Australia
|May 3, 1993
PubMed
Summary
This summary is machine-generated.

The risk of erythromycin-associated cholestatic hepatitis is low, estimated at 3.6 cases per 100,000 users. This study quantifies the risk of this rare liver disorder following erythromycin use.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing full-field data from structural components with complicated geometries.

Royal Society open science·2021
Same author

Effects of chronic hypoxia on diaphragm function in deer mice native to high altitude.

Acta physiologica (Oxford, England)·2018
Same author

Attitudes of physicians and public to pharmaceutical industry 'gifts'.

Internal medicine journal·2010
Same author

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

The Cochrane database of systematic reviews·2007
Same author

Mediastinal hibernoma simulates a malignant lesion on dual time point FDG imaging.

Lung cancer (Amsterdam, Netherlands)·2007
Same author

Cell salvage for minimising perioperative allogeneic blood transfusion.

The Cochrane database of systematic reviews·2006
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

Area of Science:

  • Hepatology
  • Pharmacovigilance
  • Clinical Epidemiology

Background:

  • Erythromycin is a macrolide antibiotic known to potentially cause cholestatic hepatitis.
  • Previous reports suggest an association between erythromycin and this liver disorder, but quantitative risk data are limited.